Risk factors for symptom relapse in patients with Los Angeles Grade A/B erosive esophagitis

被引：0

作者：

Shih, Chih-An ^{[1
,2
]}

Chuah, Seng-Kee ^{[3
]}

Hsu, Ping-, I ^{[4
]}

Lu, Ching-Liang ^{[5
]}

Kao, Sung-Shuo ^{[6
]}

Tai, Wei-Chen ^{[3
]}

Wu, I-Ting ^{[4
,11
]}

Tsai, Kun-Feng ^{[4
]}

Huang, Wen-Wei ^{[4
]}

Tang, Sheng-Yeh ^{[4
]}

Kuo, Li-Fu ^{[4
]}

Shie, Chang-Bih ^{[4
]}

Kuo, Chao-Hung ^{[7
,8
]}

Wu, Deng-Chyang ^{[7
,8
,9
,10
]}

机构：

[1] Antai Tian Sheng Mem Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Antai Med Care Corp, Pingtung, Taiwan

[2] Meiho Univ, Dept Nursing, Pingtung, Taiwan

[3] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan

[4] China Med Univ, An Nan Hosp, Dept Internal Med, Div Gastroenterol, Tainan, Taiwan

[5] Taipei Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[6] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kaohsiung, Taiwan

[7] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[8] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan

[9] Kaohsiung Med Univ Hosp, Dept Med, Div Gastroenterol, 100, Tzyou 1st Rd, Kaohsiung 807377, Taiwan

[10] Kaohsiung Med Univ, Coll Med, 100, Tzyou 1st Rd, Kaohsiung 8007377, Taiwan

[11] China Med Univ, An Nan Hosp, 66, Sect 2,Changhe Rd, Tainan 709204, Taiwan

来源：

ADVANCES IN DIGESTIVE MEDICINE | 2024年 / 11卷 / 02期

关键词：

erosive esophagitis; gastroesophageal reflux disease; proton pump inhibitor; relapse; GASTROESOPHAGEAL-REFLUX DISEASE; CIGARETTE-SMOKING; ASSOCIATION; BURDEN; LIFE;

D O I：

10.1002/aid2.13380

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Recurrence of reflux symptoms following discontinuing proton pump inhibitor therapy is a common problem in the treatment of gastroesophageal reflux disease. We aim (1) to examine the cumulative 12-week incidence of symptom relapse following 8-week proton pump inhibitor therapy in patients with Los Angeles grade A/B erosive esophagitis and (2) to search the risk factors predicting symptom relapse in the treatment of erosive esophagitis. From June 2010 to May 2019, patients with Los Angeles Grade A/B erosive esophagitis receiving esomeprazole therapy (40 mg qd) for 8 weeks followed by complete symptom resolution were included in this study. Subjects received on-demand esomeprazole treatment for 12 weeks and underwent prospective follow-up for reflux symptoms. 12-week cumulative incidence of symptom relapse was assessed, and predictive risk factors for symptom relapse were determined by multivariate analysis. 219 patients with Los Angeles Grade A/B erosive esophagitis who achieved complete symptom resolution following 8-week esomeprazole therapy were enrolled. During the 12-week follow-up period, 110 patients (50.2%) developed symptom relapse. Univariate analysis showed that symptom relapse was significantly associated with advanced age, smoking, and the presence of heartburn (p = .003, .015, and .042, respectively). Multivariate analysis with stepwise logistic regression showed that only advanced age (95% confidence interval [CI]: 1.45-5.15) and smoking (95% CI: 1.30-6.58) were independent factors predicting symptom relapse with odds ratios of 2.74 and 2.92, respectively. The 12-week cumulative incidence of symptom relapse following initial proton pump inhibitor treatment in patients with Los Angeles grade A/B erosive esophagitis is 50.2%. Advanced age and smoking are independent risk factors predicting symptom relapse following treatment in patients with mild erosive esophagitis.

引用

页码：94 / 100

页数：7

共 26 条

[11] Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole [J].